Note: This document has been translated from the Japanese original for reference purposes only. In the event ofany discrepancy between this translated document and the Japanese original, the original shall prevail.

November 10, 2022
Company
Headquarters
Representative
Contact
Telephone
WebsiteTakara Bio Inc. (Securities code: 4974;Prime Market)
Nojihigashi 7-4-38, Kusatsu, Shiga, Japan
Koichi Nakao, President & CEO
Takuya Kakemi, Executive Officer, in chargeof PR & IR Department(+81)77-565-6970
https://www.takara-bio.co.jp/Notice Concerning Revisions to the Financial Results Forecasts
and Dividend Forecasts (Dividend Increase)

Takara Bio Inc. (the “Company”) hereby announces that in the light of the most recent operating trends, to revise
the financial results forecasts for the fiscal year ending March 31, 2023 (April 1, 2022 – March 31, 2023), disclosed
on May 12, 2022, and the year-end dividend forecasts for the year ending March 31, 2023, as described below.
1. Revisions to financial results forecasts(1) Revisions to consolidated financial results forecasts for the full year of the current fiscal year (April 1, 2022
through March 31, 2023)
Net income
attributable toowners of the parent

Net income
per share

Million yen

Million yen

Yen

15,00015,10010,60088.03

77,80019,00019,10013,800114.60Change (B-A)

22,500

4,000

4,000

3,200-

Change (%)

40.7

26.7

26.5

30.2

-

67,69928,90228,45919,849164.84

Net sales

OperatingprofitOrdinaryprofit

Million yen

Million yen

55,300

Revised forecasts (B)Previously announced
forecasts (A)(Reference)
Actualconsolidated results
for the previous fiscalyear (Fiscal year
ended March 31,2022)

(2) Reason for revision
Sales are expected to be higher than previously announced forecasts for Reagents, Instruments, and Gene
Therapy, although CDMO is expected to be lower than previous announced forecast. In particular, general
research reagents and the new Coronavirus testing reagents are expected to exceed the previously announced
forecasts. Gross profit is expected to increase due to the increase in sales, so operating profit, ordinary profit,
and net income attributable to owners of the parent are also expected to exceed the previously announced
forecasts. Therefore, the forecasts of the consolidated financial results for the full year has been revised.
For details of the forecasts announced this time, please refer to page 12 of the “Consolidated FinancialResults for the Six Months Ended September 30, 2022 (Under Japanese GAAP)” announced today.

2. Revisions to dividend forecasts(1) Details of revision
Annual dividends (Yen)
Second quarter-end

Fiscal-year end

Total

Previous forecasts

33.00

33.00

Revised forecasts

40.00

40.00

33.00

33.00

Actual results for the current fiscal year
Actual results for the previous fiscal year
(Fiscal year ended March 31, 2022)

0.00
0.00

(2) Reason for revision
We consider returning profits to shareholders to be an important management issue, while paying attention toenhancing internal reserves in order to actively implement R&D activities in both Bioindustry and Gene Therapy
businesses. Our basic policy is to return profits to shareholders based on a comprehensive consideration of ouroperating results and financial position. Specifically, the Company's policy is to pay dividends from retained
earnings of the high 30% range of the estimated net income, which is calculated without taking into accountextraordinary gains and losses in the consolidated financial statements.
Based on the above upward revision of the full-year consolidated financial forecast and the above shareholder
return policy, the Company has revised the year-end dividend forecasts for the year ending March 2023 from¥33.00 to ¥40.00 per share.
The year-end dividend for the fiscal year ending March 31, 2023 is scheduled to be discussed at the 21st
Ordinary General Meeting of Shareholders to be held in June 2023.

Forward-Looking Statements
Statements contained in these materials with respect to the Company’s current plans, forecasts, strategies and beliefs that are
not historical facts are forward-looking statements about the further performance of the Company and its consolidated
subsidiaries. These statements are based on management’s assumptions and beliefs in light of information currently available
to it, but are based on a number of assumptions and beliefs derived from information that contains significant risks anduncertainties. Actual results may differ materially from these forecasts due to various factors. Factors that could influence
actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as
exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and productstrategies, declines in selling power of the Company’s existing and new products, disruptions to production, violations of ourintellectual property rights, rapid advances in technology, and unfavorable verdicts in major litigation.